BioCentury
ARTICLE | Company News

Gilead pays milestone to Cubist

April 10, 2001 7:00 AM UTC

CBST received a $1.25 million milestone from GILD for meeting the primary end point in a Phase III study of its Cidecin daptomycin to treat complicated skin and soft tissue infection caused by Gram-po...